These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9165506)

  • 1. Safety assessment of tamoxifen and toremifene.
    Williams GM; Jeffrey AM
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):41-7. PubMed ID: 9165506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites.
    Cunningham A; Klopman G; Rosenkranz HS
    Mutat Res; 1996 Jan; 349(1):85-94. PubMed ID: 8569795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
    Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
    Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving role of toremifene in the adjuvant setting.
    Holli K
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
    Fan PW; Zhang F; Bolton JL
    Chem Res Toxicol; 2000 Jan; 13(1):45-52. PubMed ID: 10649966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of antiestrogens.
    Hirsimäki P; Aaltonen A; Mäntylä E
    Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation.
    Kuramochi H
    J Med Chem; 1996 Jul; 39(15):2877-86. PubMed ID: 8709121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic studies of the radical-scavenging activity of estrogens and antiestrogens.
    Fujisawa S; Kadoma Y
    Anticancer Res; 2004; 24(6):3931-7. PubMed ID: 15736434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toremifene: an evaluation of its safety profile.
    Harvey HA; Kimura M; Hajba A
    Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients.
    Marttunen MB; Andersson S; Hietanen P; Karonen SL; Koistinen HA; Koivisto VA; Tiitinen A; Ylikorkala O
    Maturitas; 2000 May; 35(2):175-9. PubMed ID: 10924844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigators involved in toremifene studies call it a potentially safer antiestrogen.
    Oncology (Williston Park); 1998 Mar; 12(3):469. PubMed ID: 9534197
    [No Abstract]   [Full Text] [Related]  

  • 14. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
    Carthew P; Edwards RE; Nolan BM
    Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity.
    Tannenbaum SR
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-81-S1-6. PubMed ID: 9045320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative effect of toremifene and tamoxifen on estrogen receptor-lacking anaplastic thyroid carcinoma cell lines.
    Kishino T; Watanabe M; Kimura M; Sugawara I
    Biol Pharm Bull; 1997 Dec; 20(12):1257-60. PubMed ID: 9448099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.
    Wiseman LR; Goa KL
    Drugs; 1997 Jul; 54(1):141-60. PubMed ID: 9211086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxic and carcinogenic effects of antipsychotics and antidepressants.
    Brambilla G; Mattioli F; Martelli A
    Toxicology; 2009 Jul; 261(3):77-88. PubMed ID: 19410629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: In search of the perfect SERM: beyond tamoxifen and raloxifene.
    Williams GM
    J Natl Cancer Inst; 1998 Nov; 90(21):1671. PubMed ID: 9811319
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.